Home -> Law Blog Directory -> Personal Injury Law Blogs -> Tampa Bay Personal Injury Law

Personal Injury Law

: Tampa Bay Personal Injury Law

Pfizer - Can It Weather the Current Storm?

By Internal Administrator

A review of Pfizer's most recent 10-K filings with the Securities & Exchange Commission leads to concerns about whether Pfizer's legal woes are quickly growing out of control.  The list of drugs that are currently subject to litigation appears to be growing longer and longer.  The filings note some of the old problems for the pharmaceutical giant - such as the horrific story of the harm inflicted on Nigerian children in connection with the controversial antibiotic Trovan, a drug that Pfizer pulled from the market in the United States several years ago after reports of drug-induced liver failure and death and Rezulin, the diabetes drug removed from the market long ago (also due to liver toxicity).

Pfizer is also facing thousands of lawsuits filed by women who developed breast cancer after ingesting various hormone replacement therapy drugs.  These HRT drugs include various products manufactured by Upjohn, Pfizer, and Novo Nordisk including Provera, Activella, Vagifem, Ogen, Estring, Depo-Estradiol, and generic medroxyprogesterone. More than five thousands lawsuits have been pending in multi-district proceedings in federal court in Little Rock. There are also more than 1,000 cases pending in state courts in Pennsylvania, New Jersey, New York, and Nevada.  It has now been nearly six years since publication of the Women's Health Initiative (WHI) study, which confirmed that the HRT drugs are promoters of hormone-positive cancers and are also associated with an increased risk of heart attacks, strokes, and ovarian cancer. The WHI Study and other recent publications have also provided further proof that many of the long-touted benefits of HRT were false.  Hopefully, the courts will continue the process of scheduling additional trials for these cases as well as establishing an orderly process for transfer of the thousands of cases pending in federal court, especially in light of the amount of time that has passed since diagnosis and the fact that many of the plaintiffs are elderly.

The 10-K filing also lists a number of additional drugs that are still presenting problems for the company. Lipitor, one of Pfizer's shining stars, has mired the company in lots of adverse publicity recently, including questions about ethics, a Congressional inquiry, and various class action and whistleblower claims have been filed in the court system.   Litigation also persists over Neurontin and improper marketing; Mirapex, a Parkinson's drug that has been linked to addictive behavior and heart valve damage; Zoloft, an anti-depressant subject to litigation over an increased rate of suicides; and Viagra, an impotence drug linked to blindness. 

Pfizer is also facing more than 1,000 lawsuits over Celebrex and Bextra.  While Celebrex remains on the market, the arthritis drug has been linked to serious cardiovascular risks such as heart attacks and strokes.  Bextra was pulled from the market in 2005 due to an increased risk of heart attacks and strokes as well, but also was pulled from the market due to reports of serious skin reactions including Stevens Johnson syndrome and erythema multiforme. Those cases are coordinated in federal court through MDL proceedings in San Francisco, and there are also coordinated proceedings in state courts as well.  The first Bextra trials will occur later this year. 

Pfizer's latest headache has come from Exubera, its inhaled insulin product.  Pfizer announced last fall that it intended to discontinue wide-scale sale of the drug due to economic reasons.  Recent studies have indicated that the drug may be causing lung cancer.  The entire Exubera saga will cost Pfizer nearly $3 billion in write-offs and charges for the once-promising new product and is a significant loss to a weak pipeline (the lifeblood for any pharmaceutical company).  Only time will tell whether Exubera also becomes the most recent entry on the vast list of fallen drugs that are now causing headaches for Pfizer's legal department and its bottom line. 

 

 

 

 

Full post as published by Tampa Bay Personal Injury Law on April 14, 2008 (boomark / email).